OM1 does not apply inclusion or exclusion selection criteria for patients specific to their %BSA values and targeted therapies. Further, our Managing Director for Dermatology confirmed that the uniformity of BSA values across therapies observed in the data is reflected in clinical practice.
Once a patient qualifies for a biologic (>8% BSA or special areas) the choice is largely driven by (1) insurance coverage and/or (2) provider preference.
Category:
Psoriasis